Alpha 2.0
Login Register
» Authors » Herman Oostermeijer

Herman Oostermeijer

Explore the profile of Herman Oostermeijer including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 10
Citations 226
Followers 0
Related Specialties
Science
General Medicine
Microbiology
Top 10 Co-Authors
Petra Mooij
Gerrit Koopman
Jonathan L Heeney
Ernst J Verschoor
Willy M J M Bogers
Willy M Bogers
Daniella Mortier
Ivanela Kondova
Edmond J Remarque
Zahra Fagrouch
Published In
NPJ Vaccines
PLoS One
AIDS
J Infect Dis
Proc Natl Acad Sci U S A
Affiliations
Soon will be listed here.
Recent Articles
1.
Sterile protection against relapsing malaria with a single-shot vaccine
Pasini E, van der Wel A, Heijmans N, Klop O, Zeeman A, Oostermeijer H, et al.
NPJ Vaccines . 2022 Oct; 7(1):126. PMID: 36302860
Vaccine development for Plasmodium vivax, an important human relapsing malaria, is lagging behind. In the case of the most deadly human malaria P. falciparum, unprecedented high levels of protection have...
2.
The Post-Acute Phase of SARS-CoV-2 Infection in Two Macaque Species Is Associated with Signs of Ongoing Virus Replication and Pathology in Pulmonary and Extrapulmonary Tissues
Boszormenyi K, Stammes M, Fagrouch Z, Kiemenyi-Kayere G, Niphuis H, Mortier D, et al.
Viruses . 2021 Aug; 13(8). PMID: 34452537
The post-acute phase of SARS-CoV-2 infection was investigated in rhesus () and cynomolgus macaques (). During the acute phase of infection, SARS-CoV-2 was shed via the nose and throat, and...
3.
Accelerated phase Ia/b evaluation of the malaria vaccine candidate PfAMA1 DiCo demonstrates broadening of humoral immune responses
Remarque E, Faber B, Rodriguez Garcia R, Oostermeijer H, Sirima S, Ouedraogo I, et al.
NPJ Vaccines . 2021 Apr; 6(1):55. PMID: 33854065
Plasmodium falciparum apical membrane antigen 1 (PfAMA1) is a candidate malaria vaccine antigen expressed on merozoites and sporozoites. PfAMA1's polymorphic nature impacts vaccine-induced protection. To address polymorphism, three Diversity Covering...
4.
Increased, Durable B-Cell and ADCC Responses Associated with T-Helper Cell Responses to HIV-1 Envelope in Macaques Vaccinated with gp140 Occluded at the CD4 Receptor Binding Site
Bogers W, Barnett S, Oostermeijer H, Nieuwenhuis I, Beenhakker N, Mortier D, et al.
J Virol . 2017 Jul; 91(19). PMID: 28701402
Strategies are needed to improve the immunogenicity of HIV-1 envelope (Env) antigens (Ag) for more long-lived, efficacious HIV-1 vaccine-induced B-cell responses. HIV-1 Env gp140 (native or uncleaved molecules) or gp120...
5.
Pandemic Swine-Origin H1N1 Influenza Virus Replicates to Higher Levels and Induces More Fever and Acute Inflammatory Cytokines in Cynomolgus versus Rhesus Monkeys and Can Replicate in Common Marmosets
Mooij P, Koopman G, Mortier D, van Heteren M, Oostermeijer H, Fagrouch Z, et al.
PLoS One . 2015 May; 10(5):e0126132. PMID: 25946071
The close immunological and physiological resemblance with humans makes non-human primates a valuable model for studying influenza virus pathogenesis and immunity and vaccine efficacy against infection. Although both cynomolgus and...
6.
Vaccine-induced protection of rhesus macaques against plasma viremia after intradermal infection with a European lineage 1 strain of West Nile virus
Verstrepen B, Oostermeijer H, Fagrouch Z, van Heteren M, Niphuis H, Haaksma T, et al.
PLoS One . 2014 Nov; 9(11):e112568. PMID: 25392925
The mosquito-borne West Nile virus (WNV) causes human and animal disease with outbreaks in several parts of the world including North America, the Mediterranean countries, Central and East Europe, the...
7.
Potent immune responses in rhesus macaques induced by nonviral delivery of a self-amplifying RNA vaccine expressing HIV type 1 envelope with a cationic nanoemulsion
Bogers W, Oostermeijer H, Mooij P, Koopman G, Verschoor E, Davis D, et al.
J Infect Dis . 2014 Sep; 211(6):947-55. PMID: 25234719
Self-amplifying messenger RNA (mRNA) of positive-strand RNA viruses are effective vectors for in situ expression of vaccine antigens and have potential as a new vaccine technology platform well suited for...
8.
Systemic neutralizing antibodies induced by long interval mucosally primed systemically boosted immunization correlate with protection from mucosal SHIV challenge
Bogers W, Davis D, Baak I, Kan E, Hofman S, Sun Y, et al.
Virology . 2008 Oct; 382(2):217-25. PMID: 18947849
Immune correlates of vaccine protection from HIV-1 infection would provide important milestones to guide HIV-1 vaccine development. In a proof of concept study using mucosal priming and systemic boosting, the...
9.
Aerosol immunization with NYVAC and MVA vectored vaccines is safe, simple, and immunogenic
Corbett M, Bogers W, Heeney J, Gerber S, Genin C, Didierlaurent A, et al.
Proc Natl Acad Sci U S A . 2008 Feb; 105(6):2046-51. PMID: 18270165
Each year, approximately five million people die worldwide from putatively vaccine-preventable mucosally transmitted diseases. With respect to mass vaccination campaigns, one strategy to cope with this formidable challenge is aerosol...
10.
A novel HIV-CCR5 receptor vaccine strategy in the control of mucosal SIV/HIV infection
Bogers W, Bergmeier L, Ma J, Oostermeijer H, Wang Y, Kelly C, et al.
AIDS . 2004 Apr; 18(1):25-36. PMID: 15090826
Objective: To develop a novel SIV-CCR5 receptor vaccine strategy that will protect macaques from SHIV infection by the vaginal mucosal route. Design: The rationale for this strategy is that humans...